Literature DB >> 25416038

VZV encephalitis that developed in an immunized patient during fingolimod therapy.

Naoum P Issa1, Afif Hentati2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25416038     DOI： 10.1212/WNL.0000000000001109

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  16 in total

Review 1.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 2.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

Review 3.  Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

Authors:  English D Willis; Meredith Woodward; Elizabeth Brown; Zoran Popmihajlov; Patricia Saddier; Paula W Annunziato; Neal A Halsey; Anne A Gershon
Journal:  Vaccine       Date:  2017-11-22       Impact factor: 3.641

Review 4.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

5.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.

Authors:  M-H Hung; Y-L Chen; P-Y Chu; C-T Shih; H-C Yu; W-T Tai; C-W Shiau; K-F Chen
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

6.  Disseminated herpes zoster with acute encephalitis in an immunocompetent elderly man.

Authors:  Jessica Hyejin Oh; Saketh Tummala; Muhammad Ghazanfar Husnain
Journal:  BMJ Case Rep       Date:  2020-06-24

Review 7.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

8.  Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.

Authors:  Andrea Harrer; Peter Wipfler; Georg Pilz; Katrin Oppermann; Elisabeth Haschke-Becher; Shahrzad Afazel; Jörg Kraus; Eugen Trinka; Johann Sellner
Journal:  Int J Mol Sci       Date:  2015-09-10       Impact factor: 5.923

Review 9.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

10.  Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Authors:  Rozita Doosti; Abdorreza Naser Moghadasi; Amir Reza Azimi; Shahrokh Karbalai Saleh; Masoud Etemadifar; Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Hossein Harirchian; Seyed Bahaadin Siroos; Hormoz Ayramloo; Nastaran Majdinasab; Seyyed Mohammad Masood Hojjati; Nabiollah Asghari; Seyed Mohammad Baghbanian; Hamed Cheraghmakani; Mahmoud Abedini; Behnaz Sedighi; Negar Mohseni Abbas Abadi; Maedeh Ghasemitabar; Sara Talebianpour; Tohid Babayi Daylari; Vahid Dana; Neda Ghaleh Noie; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.